In a report released today, Dylan Van Haaften from Stifel Nicolaus maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of €153.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dylan Van Haaften’s rating is based on several key considerations. Despite some challenges, Merck KGaA’s recent quarterly results were in line with expectations, particularly in terms of top-line revenue and EBITDA. The company has shown encouraging progress in its Life Sciences Process Solutions segment, which experienced strong organic growth driven by a recovery in pharmaceutical production demand.
While there are some headwinds, such as foreign exchange impacts and tariff uncertainties, the company’s guidance adjustments reflect a cautious but strategic approach to navigating these challenges. The Healthcare segment also demonstrated positive growth, and the Electronics division, although facing some profitability concerns, showed modest growth due to AI-driven demand. These factors, combined with a favorable upside to the price target, underpin the Buy rating given by Dylan Van Haaften.
In another report released on May 12, Barclays also maintained a Buy rating on the stock with a €160.00 price target.